izpis_h1_title_alt

Meta-analysis and experimental validation identified FREM2 and SPRY1 as new glioblastoma marker candidates
ID Vidak, Marko (Avtor), ID Jovchevska, Ivana (Avtor), ID Šamec, Neja (Avtor), ID Zottel, Alja (Avtor), ID Liović, Mirjana (Avtor), ID Rozman, Damjana (Avtor), ID Džeroski, Sašo (Avtor), ID Juvan, Peter (Avtor), ID Komel, Radovan (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (9,34 MB)
MD5: 83FE430F48BFB92CCC15C1E10F308C74
URLURL - Izvorni URL, za dostop obiščite http://www.mdpi.com/1422-0067/19/5/1369 Povezava se odpre v novem oknu

Izvleček
Glioblastoma (GB) is the most aggressive brain malignancy. Although some potential glioblastoma biomarkers have already been identified, there is a lack of cell membrane-bound biomarkers capable of distinguishing brain tissue from glioblastoma and/or glioblastoma stem cells (GSC), which are responsible for the rapid post-operative tumor reoccurrence. In order to find new GB/GSC marker candidates that would be cell surface proteins (CSP), we have performed meta-analysis of genome-scale mRNA expression data from three data repositories (GEO, ArrayExpress and GLIOMASdb). The search yielded ten appropriate datasets, and three (GSE4290/GDS1962, GSE23806/GDS3885, and GLIOMASdb) were used for selection of new GB/GSC marker candidates, while the other seven (GSE4412/GDS1975, GSE4412/GDS1976, E-GEOD-52009, E-GEOD-68848, E-GEOD-16011, E-GEOD-4536, and E-GEOD-74571) were used for bioinformatic validation. The selection identified four new CSP-encoding candidate genes-CD276, FREM2, SPRY1, and SLC47A1-and the bioinformatic validation confirmed these findings. A review of the literature revealed that CD276 is not a novel candidate, while SLC47A1 had lower validation test scores than the other new candidates and was therefore not considered for experimental validation. This validation revealed that the expression of FREM2-but not SPRY1-is higher in glioblastoma cell lines when compared to non-malignant astrocytes. In addition, FREM2 gene and protein expression levels are higher in GB stem-like cell lines than in conventional glioblastoma cell lines. FREM2 is thus proposed as a novel GB biomarker and a putative biomarker of glioblastoma stem cells. Both FREM2 and SPRY1 are expressed on the surface of the GB cells, while SPRY1 alone was found overexpressed in the cytosol of non-malignant astrocytes.

Jezik:Angleški jezik
Ključne besede:glioblastoma, glioblastoma stem cells, biomarkers, data repositories, meta-analysis, cell surface, experimental validation, FREM2, SPRY1
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2018
Št. strani:24 str.
Številčenje:Vol. 19, iss. 5, art. 1369
PID:20.500.12556/RUL-131851 Povezava se odpre v novem oknu
UDK:577
ISSN pri članku:1422-0067
DOI:10.3390/ijms19051369 Povezava se odpre v novem oknu
COBISS.SI-ID:33752793 Povezava se odpre v novem oknu
Datum objave v RUL:04.10.2021
Število ogledov:1001
Število prenosov:174
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:International journal of molecular sciences
Skrajšan naslov:Int. j. mol. sci.
Založnik:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:04.05.2018

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:glioblastom, matične celice glioblastoma, biomarkerji

Projekti

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Junior Researcher grant
Številka projekta:1240-1/2013-123-2

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0390
Naslov:Funkcijska genomika in biotehnologija za zdravje

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P2-0103
Naslov:Tehnologije znanja

Financer:EC - European Commission
Program financ.:Interreg
Akronim:TRANS-GLIOMA

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj